LIXTE Biotechnology Announces the Closing of $5.8 Million Registered Direct Offering Priced At-The-Market PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in...

Lixte Biotechnology’s LB-100 Reported to Convert Immunologically Unresponsive (“Cold”) Tumors to Immunologically Responsive (“Hot”) Tumors Outside research shows that in models of colorectal, triple-negative breast and pancreatic cancer, LB-100 induces molecular changes that render the cancers more vulnerable to immunotherapy ...

Lixte Biotechnology’s LB-100 Shown in Animal Models to Significantly Reduce Behavioral Sensitization, an Important Feature of Methamphetamine Addiction A series of recent pre-clinical reports demonstrates LB-100’s effectiveness in variousnon-neoplastic diseases that may benefit from PP2A inhibition PASADENA, CA, Aug. 17, 2021 (GLOBE NEWSWIRE) --...

Lixte Biotechnology Holdings, Inc. Announces Closing of Public Offering and Uplisting to Nasdaq East Setauket, NY, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (“Lixte” or the “Company”) (Nasdaq: Common stock – LIXT; Warrants – LIXTW), a drug discovery company that uses...

Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split East Setauket, NY, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT)(“Lixte” or the “Company”), today announced the pricing of its underwritten public offering of...